Introduction
Because of poor natural outcomes of age-related macular degeneration (AMD), and given the ever increasing prevalence of the disease, the approaches to preventive treatment at early stages of age-related maculopathy (ARM) are of special interest [1] [2] [3] .
Conventional retinal laser photocoagulation is known to carry a risk of side effects and may be followed by visual field alterations, reduction in contrast sensitivity, and development of subretinal neovascularization (SNV) [4, 5] .
It is considered that it is not necessary to damage all retinal layers in order to achieve therapeutic efficacy of laser [6] . Thus, 532-nm indirect selective retinal pigment epithelium (RPE) laser photocoagulation (LPC) has been reported to be efficacious in AMD [7] . In addition, subthreshold RPE photocoagulation with millisecond pulses from 577-nm or 810-nm laser has been found beneficial in various macular disorders [5, 6, 8, 9] . Therefore, retina-sparing laser photocoagulation can be considered as an alternative to conventional laser treatments in macular diseases like ARM.
The purpose of this study was to investigate the efficacy of 577-nm RPE LPC in the treatment of ARM with various extents of morphological and functional loss.
Materials and Methods
This was a prospective open non-controlled study on the effect of 577-nm micropulse laser photocoagulation on the retina of patients with ARM. The study was conducted at the Laser Department of the Filatov Institute and involved 57 patients (57 eyes) diagnosed with ARM. 577-nm micropulse laser photocoagulation was applied to the RPE at the macula. The primary aim was to assess the changes in visual acuity and retinal morphology at month 12 after 577-nm micropulse laser photocoagulation of the RPE at the macula. In addition, we aimed to assess the incidences of subretinal neovascularization (SNV) and geographic atrophy during the follow-up.
At baseline and at months 6 and 12, patients underwent examination including best-corrected visual acuity (BCVA) assessment, color fundus photography, optical coherence tomography (OCT; SOCT Copernicus OPTOPOL Technology S.A., Zawiercie, Poland) and retinal fluorescein angiography (FA; TRC-50EX; Topcon, Tokyo, Japan). OCT data were used to derive (1) retinal foveal thickness (RFT) and (2) diameter and height of macular drusen. Diameter and height of macular drusen were measured manually using the electronic caliper from the Copernicus software. Only the largest druse or drusenoid retinal pigment epithelium detachment (DPED) present in the eye was considered.
DPED was defined as per the AREDS study, [10] as a well-defined, pale yellow or white, large mound consisting of many large drusen or confluent drusen which was at least 350 microns in the narrowest diameter and appeareds elevated on stereoscopic fundus photographs. FA was used to reveal the signs of SNV in the macula.
All procedures were performed by one surgeon, with the laser delivered through the central part of a Goldmann three-mirror lens. The 577-nm Supra laser (Quantel Medical, Clermont-Ferrand, France) was used in the study. In micropulse laser treatment, the laser was switched to micropulse mode at 15% duty cycle (pulse train (burst time), 0.3 s; 0.17 ms ON, 1 ms OFF). Laser power was adjusted with the laser applied along the course of the vascular arcades, until grade 1 burn (according to the L'Esperance's classification) was obtained at the site of laser exposure. The eye was treated with a laser power halved to become 0.15 W to 0.45 W [11] . The laser spot size was maintained at ~100 μm. Laser was applied to the druzen-free areas of the non-foveolar macula (i.e., with the use of indirect laser photocoagulation).
All patients were followed up for 1 year and received no laser re-treatment.
Statistical analysis
Cluster analysis (Ward's method with Manhattan distance and k-means clustering) was used to determine groups of patients with similar morphological and functional values. Group means and standard deviations (SD) were calculated for all variables. Student t test and Mann-Whitney U test were used for intergroup comparisons. Statistical analysis was performed using STATISTICA 10 software (StatSoft, Inc.).
Results
Given a significant heterogeneity of the cohort (in terms of investigated parameters), Ward's clustering was used to create three groups of patients eyes with a similar extent of morphological and functional loss. It is noteworthy that k-means clustering led to the same cluster solution. Group 1 (mild baseline morphological and functional loss) involved 22 eyes having mean visual acuity of 0.68 ± 0.17, mean RFT of 203 ± 19.7 μm, and mean drusen height of 55.5 ± 6.3 μm at baseline. Group 2 (moderate baseline morphological and functional loss) involved 25 eyes with mean visual acuity of 0.3 ± 0.2, mean RFT of 269 ± 22.6 μm, and mean drusen height of 71.5 ± 6.7 μm at baseline. Group 3 (DPED group; severe baseline morphological and functional loss) involved 10 eyes with mean visual acuity of 0.22 ± 0.15, mean RFT of 311 ± 23 μm, mean DPED height of 222.5 ± 74 μm, and mean DPED diameter of 1032 ± 475 μm at baseline. There were statistically significant differences (p < 0.01) in each of the parameters between groups; the only exception was the difference (p = Over the follow-up period, we observed no cases of SNV or geographic atrophy in patients of the study.
Discussion
Authors vary in their views on how 577-nm micropulse subthreshold laser photocoagulation should be used for retinal disorders and demonstrate various approaches to titration of laser power parameters [1, 4, 7, 8, 12, 13] . We believe that the most expedient approach to titration of laser power parameters for micropulse subthreshold laser treatment is to titrate power levels in micropulse mode, and to decrease the power once the power level threshold has been identified [8, 11, 14] . Therefore, with this approach, the effect of subthreshold micropulse laser applied in the absence of retinal photocoagulation lesions becomes more predictable. The approach was mathematically substantiated and validated in our previous study on the ultrastructural changes in the rabbit chorioretinal complex following 577-nm micropulse laser photocoagulation of the fundus [11, 14] .
Gatsu et al [4] (2014) reported on the outcomes of various laser treatments for soft macular drusen in dry AMD. They used 810-nm and 532-nm lasers in subthreshold micropulse modes to deliver laser energy to the nonfoveolar macula drusen-free areas and in between them, and found subthreshold micropulse laser photocoagulation to be ineffective for soft macular drusen. Unfortunately, those authors did not specify the laser power titration procedure. In that study, however, indirect subthreshold laser photocoagulation (STLPC) and direct STLPC were found to be equally effective in terms of regression of small, soft confluent macular drusen, but resulted in no improvement in retinal functional parameters. In addition, a distinct type of drusen (so-called PED-like drusen, i.e. resembling pigment epithelium detachment) of the size greater than 800 μm, did show an improvement in the morphological appearance as well as retinal function with direct treatment [4] .
In the current study, we found improvements in morphological parameters and visual function at 12 months after indirect laser photocoagulation with a 577-nm laser in micropulse mode in patients with DPEDs greater than 350 μm in diameter.
Pasyechnikova et al [7] found selective RPE photocoagulation with millisecond pulses from a 532-laser to be efficacious for ARM, with decreased drusen height and improved visual function post treatment. In that study, drusen height and visual function, although did not change significantly in Group 1 (BCVA of 0.7 or better; RFT ≤ 200 μm; and drusen height ≤ 60 μm at baseline), did change significantly in Groups 2 and 3 (BCVA worse than 0.7; RFT > 200 μm; and drusen height > 60 μm at baseline) after treatment.
In the current study, patients with mild baseline morphological and functional loss (Group 1; mean visual acuity of 0.68±0.17, mean RFT of 203 ± 19.7 μm, and mean drusen height of 55.5±6.3 μm) demonstrated improvement in visual function and retinal morphology after subthreshold laser micropulse photocoagulation with a 577-nm laser. In addition, decreased drusen height and improved vision were also demonstrated in patients of Groups 2 and 3 at 12 months.
A 10% incidence of SNV was seen by Gatsu et al [4] at month 12 after indirect subthreshold laser treatment of drusen. In the study of Pasyechnikova et al [7] , no patient with ARM developed SNV during the 2-year followup after indirect selective RPE photocoagulation. In the present study, we observed no cases of SNV or geographic atrophy during the 12-month follow-up.
Conclusions
First, clustering was used to create three groups of age-related maculopathy eyes with a similar extent of morphological and functional loss at baseline, Group 1 (mean BCVA, 0.68±0.17; mean RFT, 203 ± 19.7 μm; mean drusen height, 55.5±6.3 μm), Group 2 (mean BCVA, 0.3 ± 0.2; mean RFT, 269 ± 22.6 μm; mean drusen height, 71.5 ± 6.7 μm), and Group 3 (mean BCVA, 0.22 ± 0.15; mean RFT, 311 ± 23 μm; mean DPED height, 222.5 ± 74 μm; mean DPED diameter, 1032 ± 475 μm).
Second, 577-nm micropulse RPE laser photocoagulation with power titrated in micropulse mode was found to be efficacious and safe treatment for agerelated maculopathy patients with a wide variation in the extent of morphological and functional loss, including patients with drusenoid pigment epithelium detachment.
Finally, in the present study, we observed no cases of SNV or geographic atrophy during the 12-month followup. 
